Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

Core Insights - Xenon Pharmaceuticals has appointed Darren Cline as Chief Commercial Officer to lead the transition to a commercial-stage company with a focus on azetukalner, which is in Phase 3 trials for epilepsy and major depressive disorder [1][2][3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for high unmet medical needs, including epilepsy and depression [5][6] - Azetukalner is a novel Kv7 potassium channel opener, currently the most advanced potassium channel modulator in late-stage clinical development [6] Leadership Appointment - Darren Cline brings over 30 years of experience in the biopharmaceutical industry, with a strong background in commercial strategy and successful product launches, particularly in epilepsy [2][3] - His previous roles include President and CEO of Epygenix Therapeutics and Chief Commercial Officer at GW Pharmaceuticals, where he contributed to the commercialization of Epidiolex [2][3] Product Development - Azetukalner is being studied in Phase 3 trials for epilepsy and major depressive disorder, with plans to initiate a trial for bipolar depression this year [1][3] - The Phase 2b X-TOLE and open label extension data support azetukalner's potential as a significant new treatment option for epilepsy [3] Compensation Details - In connection with Mr. Cline's appointment, he was granted an option to purchase 185,800 common shares at an exercise price of $31.49, with a vesting schedule over four years [4]